919363-09-0

Basic information

• Product Name: 3-broMo-2-MethylbenzaMide
• Synonyms: 3-broMo-2-MethylbenzaMide;2-Methyl-3-broMobenzaMide
• CAS NO: 919363-09-0
• Molecular Formula: C₈H₈BrNO
• Molecular Weight: 214.05922
• Mol File: 919363-09-0.mol

Chemical Properties

• Boiling Point: 270.7±33.0 °C(Predicted)
• Appearance: /
• Density: 1.522±0.06 g/cm3(Predicted)
• PKA: 15.39±0.50(Predicted)
• CAS DataBase Reference: 3-broMo-2-MethylbenzaMide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-broMo-2-MethylbenzaMide(919363-09-0)
• EPA Substance Registry System: 3-broMo-2-MethylbenzaMide(919363-09-0)

Safety Data

• Hazardous Substances Data: 919363-09-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-bromo-2-methylbenzamide is used as a raw material for the synthesis of various pharmaceutical drugs. Its unique structure and properties contribute to the development of new and effective medications.
Used in Organic Chemical Industry:
3-bromo-2-methylbenzamide serves as a building block in organic synthesis, enabling the creation of a wide range of organic compounds with diverse applications.
Used in Research and Development:
3-bromo-2-methylbenzamide is employed in research and development to study its reactivity and biological activity. This exploration aids in understanding its potential applications and further enhances its utility in the pharmaceutical and organic chemical industries.

Upstream product

• 76006-33-2 3-bromo-2-methylbenzoic acid 
• 21900-48-1 3-bromo-2-methylbenzoic acid chloride 
• 99-99-0 1-methyl-4-nitrobenzene 
• 69321-60-4 2,6-dibromotoluene 
• 101581-06-0 1,3-dibromo-2-methyl-5-nitrobenzene 
• 52780-15-1 3'-bromo-2'-methylbenzonitrile 
• 1177558-44-9 (3,5-dibromo-4-methylphenyl)amine hydrochloride 

Downstream Products

• 52780-15-1 3'-bromo-2'-methylbenzonitrile 
• 943722-02-9 [(3-Bromo-2-methylphenyl)methyl]amine 
• 1007580-28-0 4′-(1,3-dioxolan-2-yl)-3′-(trifluoromethyl)-1,1′-biphenyl-3-carboxamide 
• 943722-20-1 [(3-bromo-2-methylphenyl)methyl]amine hydrochloride 
• 1412438-57-3 2-(3-bromo-2-methyl-benzylamino)-4-thiocyanato-5-nitro pyrimidine 
• 1236133-21-3 tert-butyl N-{[trans-4-{[(2-{[(3-bromo-2-methylphenyl)methyl]amino}-5-nitropyrimidin-4-yl)amino]methyl} cyclohexyl]methyl}carbamate 
• 1412438-58-4 3'-[(4-{[trans-4-(tert-butoxycarbonylamino-methyl)-cyclohexylmethyl]-amino}-5-nitro-pyrimidin-2-ylamino)-methyl]-2'-methyl-biphenyl-3-carboxylic acid 
• 1412438-59-5 ethyl 3-[3-(aminomethyl)-2-methylphenyl]-benzoate 
• 1412438-68-6 ethyl 3-{3-[({5-cyano-4-[({4-[(tert-butoxycarbonylamino)methyl]cyclohexyl}methyl)amino]pyrimidin-2-yl}amino)methyl]-2-methylphenyl}benzoate 
• 1412438-40-4 propyl 3-[3-({[4-({[4-(aminomethyl)cyclohexyl]methyl}amino)-5-nitropyrimidin-2-yl]amino}methyl)-2-methylphenyl]benzoate 
• 1412438-71-1 3'-[(4-{[trans-4-(tert-butoxycarbonylamino-methyl)-cyclohexylmethyl]-amino}-5-nitro-pyrimidin-2-ylamino)-methyl]-2'-methyl-biphenyl-3-carboxylic acid 
• 3843-99-0 2-methyl-3-cyano-benzoic acid 
• 35256-74-7 2-methyl-3-cyano-benzoyl chloride 
• 2239273-34-6 3-(2-amino-6-(1-((6-(2-hydroxypropan-2-yl)pyridin-2-yl)methyl)-1H-1,2,3-triazol-4-yl)pyrimidin-4-yl)-2-methylbenzonitrile 

Relevant articles and documents

Development of a Scalable and Practical Synthesis of AB928, a Dual A2a/A2bReceptor Antagonist

AB928 is a potent and selective dual antagonist of the A2a and A2b receptors, which is currently in clinical trials. Here, we report the development of two scalable and practical syntheses of AB928. The first-generation synthesis was used to successfully

PROCESSES FOR PREPARING AMINOPYRIMIDINE COMPOUNDS

Provided herein are improved processes for preparing aminopyrimidine compounds of Formula (I). The disclosed processes advantageously proceed through a β-diketoester intermediate of Formula (A) and avoid the direct linking of a pyrimidine and phenyl moiet

As opioid receptor antagonists or inverse agonists of the novel compounds

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

DIFLUOROMETHYLENE COMPOUND

The present invention relates to a compound having an URAT1 inhibitory activity, and to an URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition containing the compound. More specifically, the present invention relates to a compound represented by the formula (I): wherein R1 is -Q1-A1 or the like; R2 is a hydrogen atom, a halogen atom, a lower alkyl group or the like; W1, W2, W3 and W4 are each independently a nitrogen atom or a methine group optionally having substituents, or the like; X and Y are each a single bond, an oxygen atom or the like; Z is a hydroxyl group or COOR3 or the like.

NOVEL PKC INHIBITORS

The present invention relates to new kinase inhibitors, more specifically PKCθ inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular,

Synthesis and structure-activity relationships of novel benzoxaboroles as a new class of antimalarial agents

A series of boron-containing benzoxaborole compounds was designed and synthesized for a structure-activity relationship investigation surrounding 7-(HOOCCH2CH2)-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (1) with the goal of discovering

DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS

The present invention is directed to novel compounds of Formula's (I) - (VI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of and/or prophylaxis of respiratory diseases, including inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention relates to novel compounds of Formula (I) and their use in the treatment of respiratory diseases, including anti-inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.